During the first half of 2025, Wegovy and Zepbound were among the top 10 best-selling medicines globally. The weight management market is projected to see more therapies ranked among the top-selling drugs over the next five years.

Amgen and Roche are progressing towards launching anti-obesity medications. Amgen’s leading candidate, MariTide, completed phase 2 studies last year, showing an average weight loss of up to 20%. Roche’s CT-388 had a significant placebo-adjusted 22.5% weight loss in phase 2 trials.

Amgen started phase 3 studies for MariTide last year, aiming for approval within three years. The company is also developing other promising therapies like bemarituzumab for gastric cancer and rocatinlimab for eczema, in addition to existing products like Tezspire and Repatha.

Roche’s CT-388 performed well in phase 2 studies, leading to plans for phase 3 trials this quarter. Roche also has other weight management candidates in the pipeline, including CT-996. The company has a strong portfolio, including Tecentriq and Vabysmo, contributing to its growth until 2038.

Investors should consider the potential of Amgen and Roche in the weight loss market. Amgen is a dividend stock with various promising products in its pipeline. Roche has a deep pipeline and strong growth drivers. Both companies show promise for investors looking to enter the weight management sector.

Read more at Yahoo Finance: These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys?